Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)

2017-05-10 13:53:22 | BioPortfolio


The OPTIENOX-PCI is a randomized study, which is designed to assess the anticoagulation profile of different dose regimens of enoxaparin, i.e., 0.5 mg/kg, 0.75 mg/kg, and 0.5 mg/kg with additional 0.25 mg/kg, in about 120 patients who plan to undergo elective trans-radial coronary angiography with or without subsequent PCI.


After eligible patients are randomized into Planned Staged-dose Group and Planned Single-dose Group, first-dose anticoagulation will be administered immediately. All patients in the Planned Staged-dose Group will receive enoxaparin 0.5 mg/kg at the beginning of coronary angiography and only those with definite indication for subsequent PCI will be given additional enoxaparin 0.25 mg/kg at the beginning of PCI; while, all patients in the Planned Single-dose Group will receive enoxaparin 0.75 mg/kg at the beginning of coronary angiography irrespective of their indication for subsequent PCI. Blood samples for the measurement of Anti-Xa activity will be obtained at 0 min (immediately before first-dose administration), 10 min, 90 min, 180 min after first-dose administration in all patients. Additional blood samples for Anti-Xa assessment will be collected only in patients undergoing subsequent PCI immediately before and at 10 min after the beginning of PCI, as well as at the end of PCI. The primary objective of the present study is to obtain the values of Anti-Xa activity at the above time points in each group of patients. In patients who undergo subsequent PCI, the proportion of patients with therapeutic anticoagulation (Anti-Xa 0.5-1.8 IU/ml) at 10 min after the beginning of PCI and at 90 min after first-dose administration will be compared respectively between the two groups (Staged-dose PCI Group [0.5+0.25 mg/kg] versus Single-dose PCI Group [0.75 mg/kg]). In patients who do not undergo subsequent PCI, the proportion of patients with therapeutic anticoagulation at 10 min and 90 min after first-dose administration will be compared respectively between the two groups (High-dose Group [0.75 mg/kg] versus Standard-dose Group [0.5 mg/kg]).

In conclusion, the OPTIENOX-PCI study will 1) obtain the Anti-Xa activity of enoxaparin at each time point of sampling; 2) assess the anticoagulation profile of high- versus standard-dose enoxaparin (0.75 mg/kg vs. 0.5 mg/kg), as well as that of staged- versus single-administration of high-dose enoxaparin (0.5+0.25 mg/kg vs. 0.75 mg/kg). The result of the present study will provide pharmacodynamical data for the design of future outcome studies.

Study Design


Coronary Artery Disease


Enoxaparin (Staged-dose PCI Group), Enoxaparin (Single-dose PCI Group), Enoxaparin (High-dose Group), Enoxaparin (Standard-dose Group)


Peking Union Medical College Hospital


Not yet recruiting


Peking Union Medical College Hospital

Results (where available)

View Results


Published on BioPortfolio: 2017-05-10T13:53:22-0400

Clinical Trials [11651 Associated Clinical Trials listed on BioPortfolio]

Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

The main objective of this study is to determine the time interval following the last treatment dose of enoxaparin at which the amount of anti-Xa level activity is reliably less than 0.2IU...

Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients

The aim of this research is to better understand how patient-level factors can be used to predict the appropriate enoxaparin dose to maximize venous thromboembolism (VTE) risk reduction an...

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Single, Escalating Doses of PER977 Following a Single Dose of Enoxaparin

PER977 administration following a single subcutaneous (sc) dose of enoxaparin 1.5 mg/kg will have an acceptable safety and tolerability profile with no impact on pro-coagulant biomarkers.

Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer

This is a randomized, single blind, multi-center, phase two clinical trial. Inclusion criteria are consist of non-metastatic esophageal cancer who are going to receive chemo-radiotherapy. ...


Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as single therapy or in combination with Enoxaparin in patients aged older than 18 years with locally advanced or ...

PubMed Articles [21653 Associated PubMed Articles listed on BioPortfolio]

Enoxaparin 40mg per day is Inadequate for Venous Thromboembolism Prophylaxis After Thoracic Surgery.

Many thoracic surgery patients have venous thromboembolism (VTE) events despite the receipt of chemical prophylaxis. Enoxaparin's pharmacologic impact can be quantified using anti-Factor Xa (aFXa) lev...

Pharmacokinetics of Enoxaparin After Renal Transplantation in Pediatric Patients.

Enoxaparin is commonly used in the prevention of renal allograft vascular thrombosis but off-label in children, and no consensus exists regarding the optimal dosing and dose adjustment. In this retros...

The impact of once versus twice daily enoxaparin prophylaxis on risk for venous thromboembolism and clinically relevant bleeding.

Venous thromboembolism (VTE) is a life or limb threatening complication that occurs in plastic surgery patients. At present, the optimal dose of enoxaparin that balances the risk of VTE and the risk o...

Twice daily enoxaparin among plastic surgery inpatients: an examination of pharmacodynamics, 90-day VTE, and 90-day bleeding.

Low anti-Factor Xa (aFXa) level, indicative of inadequate enoxaparin dosing, has a significant association with 90-day venous thromboembolism (VTE) events. We examined the pharmacodynamics of enoxapar...

Ameliorating effects of tempol on methotrexate-induced liver injury in rats.

Methotrexate (MTX) is used in the treatment of certain types of cancers and chronic inflammatory illnesses, although the clinical use of MTX is limited due to its adverse effects, the most common of w...

Medical and Biotech [MESH] Definitions

The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.

A treatment schedule in which the total dose of radiation is divided into large doses.

Mice selectively bred for hypersusceptibility to two-stage chemical skin carcinogenesis. They are also hypersusceptible to UV radiation tumorigenesis with single high-dose, but not chronic low-dose, exposures. SENCAR (SENsitive to CARcinogenesis) mice are used in research as an animal model for tumor production.

The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)

Administration of the total dose of radiation (RADIATION DOSAGE) in parts, at timed intervals.

More From BioPortfolio on "Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)"

Quick Search


Relevant Topic

Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...

Searches Linking to this Trial